Marta Sevieri, Francesco Andreata, Francesco Mainini, Lorena Signati, Francesca Piccotti, Marta Truffi, Arianna Bonizzi, Leopoldo Sitia, Claudia Pigliacelli, Carlo Morasso, Barbara Tagliaferri, Fabio Corsi, Serena Mazzucchelli
Despite the advent of numerous targeted therapies in clinical practice, anthracyclines, including doxorubicin (DOX), continue to play a pivotal role in breast cancer (BC) treatment. DOX directly disrupts DNA replication, demonstrating remarkable efficacy against BC cells. However, its non-specificity toward cancer cells leads to significant side effects, limiting its clinical utility. Interestingly, DOX can also enhance the antitumor immune response by promoting immunogenic cell death in BC cells, thereby facilitating the presentation of tumor antigens to the adaptive immune system...
April 15, 2024: Journal of Nanobiotechnology